top of page

HCW 2026: Scribe Therapeutics, which represents the next generation of CRISPR, had its IPO in July - the first clinical program targets PCSK9

6 minutes ago

1 min read

Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3.

https://vimeo.com/1227060752?share=copy&fl=sv&fe=ci

Coverage brought to you by

Recent Posts

HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader

HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader

HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications

HCW 2026: With an in-human proof of concept in hand from a rare condition, Prime Medicine is ready to go broader in new indications

HCW 2026: H.C. Wainwright & Co.'s Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while

HCW 2026: H.C. Wainwright & Co.'s Managing Director of Healthcare Investment Banking James Cappuccio says that smaller biotech companies are now able to do large raises for the first time in a while

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

10x_Genomics_logo.svg.png

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page